TL;DR
- What: Centrophenoxine (meclofenoxate) is a choline precursor ester that clears lipofuscin — the cellular garbage that accumulates with age.
- Mechanism: Delivers DMAE past the blood-brain barrier more efficiently than DMAE alone; donates p-chlorophenoxyacetate for antioxidant defense; mobilizes lipofuscin from lysosomes.
- Who it’s for: Men over 40 focused on cognitive longevity.
- Differentiator: One of the few compounds that actively removes accumulated aging byproducts rather than just adding substrate.
- Natural Plus angle: Dosed at 250-750 mg, cycled, stacked with choline and omega-3.
Deep Biochemistry
Centrophenoxine is dimethylaminoethanol (DMAE) esterified with p-chlorophenoxyacetic acid (pCPA). The ester bond solves DMAE’s big problem — DMAE alone has poor CNS penetration because it’s polar. pCPA makes the molecule lipophilic enough to cross the blood-brain barrier, where esterases cleave it, releasing DMAE inside neurons.
DMAE is a precursor to phosphatidylcholine and, more interestingly, a putative precursor to choline and acetylcholine synthesis in brain. But centrophenoxine’s unique claim is lipofuscin clearance. Lipofuscin is an intracellular pigment composed of oxidized, cross-linked protein-lipid aggregates that accumulates in post-mitotic cells (neurons, cardiomyocytes) and is considered a biomarker of aging. Animal studies since the 1970s show centrophenoxine reduces lipofuscin deposits in neurons.
The pCPA moiety has intrinsic hydroxyl-radical scavenging activity. Half-life is ~4-6 hours. Bioavailability after oral dosing is adequate; most users take divided doses.
Tony Huge Laws of Biochemistry Physics Applied
This compound illustrates Law 4 of the Tony Huge Laws of Biochemistry Physics — Self-Regulating Systems. The aging cell is a self-regulating system — autophagy and lysosomal clearance normally recycle damaged proteins and lipids. As we age, these systems slow, and lipofuscin accumulates because the feedback that should trigger clearance is blunted. Centrophenoxine works with the self-regulating system: it accelerates lipofuscin clearance so the cell’s own housekeeping machinery can do its job. You are not overriding the system — you are unblocking its bottleneck. This is the thermostat analogy in action: fix the sensor, don’t just crank the heat.
Natural Plus Protocol
- Dose: 250-750 mg/day, divided 2x.
- Timing: AM and early afternoon with food.
- Cycling: 8 weeks on, 2 weeks off.
- Stack partners: Alpha-GPC (choline), DHA, B-complex.
- Bloodwork: No required panel. Neuropsych self-testing (N-back, Stroop) at baseline and week 8 is recommended.
Stacking Recommendations
| Stack Compound | Pathway | Why It Synergizes |
|---|---|---|
| Alpha-GPC | Choline donor | Supports the acetylcholine pathway centrophenoxine feeds into. |
| PQQ | Mitochondrial biogenesis | Independent pathway — pairs cellular cleanup with new mitochondria. |
| Methylene Blue | Electron transport chain | Different mechanism of antioxidant support; synergistic at low doses. |
Target Audience
Men over 40 noticing subtle cognitive decline. Former boxers or athletes with history of concussion. Anyone focused on cognitive longevity rather than acute stimulation.
Timeline / Results Table
| Timeframe | What to Expect |
|---|---|
| Week 1-2 | Mild cognitive sharpening; some users report vivid dreams. |
| Week 4 | Measurable improvement in working memory tasks. |
| Week 8 | Subjective clarity and verbal fluency noticeably improved. |
| Week 12 | Cycle off. Stable gains suggest genuine cellular cleanup. |
Interesting Perspectives
Centrophenoxine is one of the oldest nootropics studied — developed in France in the late 1950s, still prescribed in some European countries for age-related cognitive decline. Hungarian researcher Zs.-Nagy built the “membrane hypothesis of aging” around centrophenoxine’s effects on lipofuscin. That framework has been largely validated: lipofuscin is now widely accepted as a marker of cellular aging.
Contrarian take: most modern nootropic marketing ignores centrophenoxine because it’s old, off-patent, and produces no acute feeling. Underground longevity researchers rate it highly specifically because the effect is structural, not symptomatic.
Emerging angle: lysosomal dysfunction is a central node in multiple neurodegenerative diseases. Compounds that enhance lysosomal clearance — centrophenoxine, spermidine, trehalose — are converging as a distinct therapeutic class.
FAQ
What is centrophenoxine?
Centrophenoxine (meclofenoxate) is a nootropic that delivers DMAE across the blood-brain barrier and helps clear lipofuscin — cellular aging waste.
How much centrophenoxine should I take?
250-750 mg per day, divided into two doses, with food.
Is it safe long-term?
Decades of European clinical use show a clean profile. Cycle 8 weeks on, 2 off to avoid potential tolerance.
Can I stack with other nootropics?
Yes — pairs well with Alpha-GPC, PQQ, and methylene blue.
Who should use centrophenoxine?
Men over 40 focused on cognitive longevity and clearing accumulated cellular aging byproducts.
References
- Zs.-Nagy I. “A proposal for reconsideration of the role of membrane structural changes in aging.” Ann N Y Acad Sci, 1994.
- Nandy K. “Effects of centrophenoxine on the lipofuscin pigments in neurons.” J Gerontol, 1978.
- Marcer D, Hopkins SM. “The differential effects of meclofenoxate on memory loss in the elderly.” Age Ageing, 1977.
- Pek G, et al. “Effects of meclofenoxate on central nervous system aging.” Exp Gerontol, 1989.
- Liao Y, et al. “Lipofuscin: formation, distribution, and metabolic consequences.” Ann N Y Acad Sci, 2008.
Related Reading
Compare to Alpha-GPC vs CDP-Choline, read about PQQ for mitochondrial biogenesis, and see the Enhanced Athlete Protocol supplement stack.